Affiliation:
1. Peoples' Friendship University of Russia named after Patrice Lumumba
2. Peoples' Friendship University of Russia named after Patrice Lumumba; City Clinical Hospital No. 24 of the Moscow City Health Department
Abstract
Relevance. Colon and ovarian cancer occupy leading positions in the structure of morbidity and mortality among malignant neoplasms in Russia. One of the widely used drugs for the treatment of these nosologies is oxaliplatin, but there is no relevant information to assess its availability and share among other antitumor drugs.Objective. Analysis of the Russian pharmaceutical market for oxaliplatin drugs among other antitumor drugs in 2015–2022.Materials and methods. For the analysis, reports from marketing agencies DSM Group and IMS were used, both in value and in physical terms.Results. During the period under study, significant changes occurred in the Russian pharmaceutical market of antitumor drugs: the volume of sales and consumption increased, which was also accompanied by a decrease in the cost of drug units per package (all antitumor drugs) and course of use (oxaliplatin). At the same time, the share of Russian manufacturers of antitumor drugs has increased. In relation to oxaliplatin, during the study period there was almost complete displacement of the original drug from the market by generic drugs. An intensive process of import substitution was also observed: the share of domestic drugs increased by the end of the study period in value and volume terms to 93 and 95%, respectively.Conclusion. Identified changes in the Russian pharmacological market for 2015–2022 reflect an increase accompanied by an increase in the availability of antitumor drugs and, in particular, oxaliplatin.